Erste Group Bank Issues Optimistic Estimate for ABT Earnings

Posted by Brenda Bartman on Jul 30th, 2026

Abbott Laboratories (NYSE:ABT – Free Report) – Stock analysts at Erste Group Bank increased their FY2026 earnings per share (EPS) estimates for shares of Abbott Laboratories in a report issued on Monday, July 27th. Erste Group Bank analyst H. Engel now forecasts that the healthcare product maker will post earnings per share of $5.52 for the year, up from their prior forecast of $5.47. The consensus estimate for Abbott Laboratories’ current full-year earnings is $5.52 per share.

A number of other research analysts have also recently commented on ABT. Daiwa Securities Group cut Abbott Laboratories from an “outperform” rating to a “neutral” rating and set a $92.00 price target on the stock. in a report on Wednesday, April 22nd. Raymond James Financial reduced their price objective on shares of Abbott Laboratories from $130.00 to $115.00 and set an “outperform” rating on the stock in a research report on Friday, April 17th. Piper Sandler reissued an “overweight” rating and issued a $118.00 target price (up from $115.00) on shares of Abbott Laboratories in a report on Friday, July 17th. Stifel Nicolaus dropped their target price on shares of Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating for the company in a research report on Friday, April 17th. Finally, Argus reduced their price target on shares of Abbott Laboratories from $140.00 to $125.00 and set a “buy” rating on the stock in a report on Tuesday, April 21st. Three research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $118.17.

Read Our Latest Research Report on Abbott Laboratories

Abbott Laboratories Trading Up 0.8%

NYSE:ABT opened at $108.15 on Thursday. Abbott Laboratories has a one year low of $81.97 and a one year high of $137.49. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.39 and a quick ratio of 1.01. The firm has a market capitalization of $188.38 billion, a price-to-earnings ratio of 35.00, a price-to-earnings-growth ratio of 2.08 and a beta of 0.61. The business has a fifty day moving average price of $92.72 and a 200-day moving average price of $100.73.

Abbott Laboratories (NYSE:ABT – Get Free Report) last issued its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.28 by $0.03. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.65%. The business had revenue of $12.59 billion during the quarter, compared to analysts’ expectations of $12.52 billion. During the same period in the previous year, the company earned $1.26 earnings per share. The business’s revenue for the quarter was up 13.0% compared to the same quarter last year. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS.

Abbott Laboratories Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th will be paid a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 2.3%. The ex-dividend date of this dividend is Wednesday, July 15th. Abbott Laboratories’s payout ratio is presently 81.55%.

Institutional Investors Weigh In On Abbott Laboratories

Several institutional investors have recently made changes to their positions in ABT. Cornerstone Financial Management LLC purchased a new position in shares of Abbott Laboratories during the 4th quarter worth about $25,000. MidAtlantic Capital Management Inc. bought a new stake in Abbott Laboratories in the fourth quarter worth about $25,000. Purpose Unlimited Inc. purchased a new position in shares of Abbott Laboratories during the fourth quarter valued at approximately $25,000. Portfolio Resources Advisor Group Inc. purchased a new stake in shares of Abbott Laboratories in the fourth quarter worth approximately $26,000. Finally, Abound Financial LLC bought a new stake in shares of Abbott Laboratories during the 4th quarter worth approximately $26,000. Institutional investors own 75.18% of the company’s stock.

Abbott Laboratories News Summary

Here are the key news stories impacting Abbott Laboratories this week:

Positive Sentiment: Erste Group Bank raised its FY2026 EPS estimate for Abbott Laboratories (ABT) to $5.52 from $5.47, in line with consensus. The firm also nudged its FY2027 forecast higher to $6.06 from $6.05, reinforcing expectations for continued earnings growth. Erste Group Bank earnings estimate update
Positive Sentiment: UBS maintained a Buy rating on ABT, despite reducing its price target to $125 from $135. The revised target still implies meaningful upside from the referenced $108.15 share price, indicating that UBS continues to view Abbott’s fundamentals favorably. UBS Abbott price target update
Positive Sentiment: TD Cowen reiterated a Buy rating and a $115 price target, citing a strengthening nutrition franchise and 2026 growth drivers. This adds to the positive analyst support following Abbott’s recent earnings beat. TD Cowen Abbott Buy rating
Positive Sentiment: Abbott has begun a study of approximately 1,000 patients to assess the real-world safety and performance of its TriClip heart-valve repair system. The study could help support adoption and competitiveness against Edwards Lifesciences, although it also highlights increasing competition in the market. Abbott TriClip study
Neutral Sentiment: Recent coverage continues to highlight Abbott’s exposure to diabetes care, oncology diagnostics, nutrition and cardiovascular devices. These are attractive long-term growth areas, but the reports provide limited new financial information beyond the company’s existing strategy. Abbott growth opportunities
Negative Sentiment: UBS’s reduction of its price target from $135 to $125 signals more measured near-term valuation expectations. Although the Buy rating was retained, the target cut may limit enthusiasm, particularly given ABT’s elevated valuation relative to its historical trading range. UBS lowers Abbott expectations

Abbott Laboratories Company Profile

(Get Free Report)

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.